June 22, 2017 08:06 AM EDT

In another setback, Kamada pulls an application at the EMA and retrenches on a PhIII drug

Two weeks after Shire punted rights to one of its therapies, Israel’s Kamada $KMDA says that it is yanking its marketing application at the EMA …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In an­oth­er set­back, Ka­ma­da pulls an ap­pli­ca­tion at the EMA and re­trench­es on a PhI­II drug